Brief: Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly
27/03/2025 20:59
March 27 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O: CRINETICS PHARMACEUTICALS ANNOUNCES EUROPEAN MEDICINES AGENCY (EMA) VALIDATION OF MARKETING AUTHORIZATION APPLICATION (MAA) AND ORPHAN DRUG DESIGNATION (ODD) FOR PALTUSOTINE IN ACROMEGALY Source text: ID:nGNX7PGfB0 Further company coverage: CRNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crinetics Pharmaceuticals
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Crinetics Q2 revenue jumps on PALSONIFY launch, withdraws guidance
Brief: Crinetics Pharmaceuticals Q2 Net Income USD -120.855 Million